Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that multiple abstracts featuring clinical and preclinical data on the Company’s pipeline candidates for the treatment of thyroid eye disease (TED) will be presented at the following medical meetings: The 45th Annual Meeting of the European Thyroid Association (ETA) to be he